Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**TransipegLib** is an iso-osmotic laxative formulation containing **5.9 g macrogol 3350 (polyethylene glycol 3350)** per sachet, combined with electrolytes (sodium chloride, anhydrous sodium sulfate, potassium chloride, sodium bicarbonate) for the treatment of **occasional constipation in adults**. It works by retaining water in the intestinal lumen through hydrogen bonding, increasing stool hydration and volume to promote bowel movements, with effects typically within **24-48 hours**. Lemon-flavored powder for oral solution, dosed 1-2 sachets daily (dissolved in 100 ml water), not exceeding one week without medical advice; contains notable excipients including **290 mg sodium**, **40 mg potassium**, and **aspartame** (contraindicated in phenylketonuria).[1][2][4]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TransipegLib.